A ≥1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse

References

• Downing J R, Head D R, Curcio-Brint A M, Hulshof M G, Motroni T A, Raimondi S C, et al. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 1993; 81: 2860–2865
   PubMed Web of Science ®Google Scholar
• Liu P, Tarle S A, Hajra A, Claxton D F, Marlton P, Freedman M, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261: 1041–1044
   PubMed Web of Science ®Google Scholar
• Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E, et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 2002; 16: 1176–1181
   PubMed Web of Science ®Google Scholar
• Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans P A, et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000; 95: 815–819
   PubMed Web of Science ®Google Scholar
• Marcucci G, Caligiuri M A, Dohner H, Archer K J, Schlenk R F, Dohner K, et al. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 2001; 15: 1072–1080
   PubMed Web of Science ®Google Scholar
• van der Reijden B A, Simons A, Luiten E, van der Poel S C, Hogenbirk P E, Tonnissen E, et al. Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion. Br J Haematol 2002; 118: 411–418
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Cayuela J M, Martini S, Baruchel A, Rousselot P, Socie G, et al. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. J Clin Oncol 2000; 18: 788–794
   PubMed Web of Science ®Google Scholar
• Stentoft J, Hokland P, Ostergaard M, Hasle H, Nyvold C G. Minimal residual core binding factor AMLs by real time quantitative PCR – initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res 2006; 30: 389–395
   PubMed Web of Science ®Google Scholar
• Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F, et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002; 99: 443–449
   PubMed Web of Science ®Google Scholar
• Viehmann S, Teigler-Schlegel A, Bruch J, Langebrake C, Reinhardt D, Harbott J. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia 2003; 17: 1130–1136
   PubMed Web of Science ®Google Scholar
• Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003; 102: 2746–2755
   PubMed Web of Science ®Google Scholar
• Leroy H, de Botton S, Grardel-Duflos N, Darre S, Leleu X, Roumier C, et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia 2005; 19: 367–372
   PubMed Web of Science ®Google Scholar
• Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 2003; 21: 4413–4422
   PubMed Web of Science ®Google Scholar
• Perea G, Lasa A, Aventin A, Domingo A, Villamor N, Queipo de Llano M P, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 2006; 20: 87–94
   PubMed Web of Science ®Google Scholar
• Krauter J, Hoellge W, Wattjes M P, Nagel S, Heidenreich O, Bunjes D, et al. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. Genes Chromosomes Cancer 2001; 30: 342–348
   PubMed Web of Science ®Google Scholar
• Saal R J, Gill D S, Coboroft R G, Marlton P. Quantitation of AML-ETO transcripts using real time PCR on the AB17700 sequence detection system. Blood (Suppl.) 1998; 92: 301
   Google Scholar
• Cheson B D, Bennett J M, Kopecky K J, Buchner T, Willman C L, Estey E H, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642–4649
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Cimino G, Breccia M, Noguera N I, Diverio D, Finolezzi E, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104: 1995–1999
   PubMed Web of Science ®Google Scholar
• Doubek M, Brychtova Y, Berkovcova J, Krejci M, Palasek I, Dvorakova D, et al. Acute myeloid leukemias with recurrent genetic abnormalities: frequent assessment of minimal residual disease and treatment of molecular relapse with chemotherapy. Leukemia 2005; 19: 885–888
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden V H, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia – a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357
   PubMed Web of Science ®Google Scholar